Cardiovascular Drugs and Therapy

, Volume 14, Issue 1, pp 49–53 | Cite as

Benefit of Antihypertensive Treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) Trial

  • Jerzy Gasowski
  • Willem H. Birkenhäger
  • Jan A. Staessen
  • Peter W. de Leeuw
Article

Abstract

In this review we attempt to determine the role of calcium channel blockers in preventing cardiovascular sequelae in patients with both hypertension and diabetes mellitus. The data have been collected from three sources: post-hoc analyses of subgroups of diabetic patients in placebo-controlled hypertension trials (SHEP, Syst-Eur, Syst-China); stepped-care blood pressure-oriented trials (HOT, UKPDS); and comparative trials focusing primarily on metabolic aspects and intermediate endpoints (ABCD, FACET).

On balance, the data seem to indicate that long-acting calcium channel blockers score remarkably well in preventing cardiovascular complications in diabetic hypertensive patients.

hypertension diabetes prospective antihypertensive trials trial endpoints dihydropiridine-type long-acting calcium channel blockers ACE inhibitors diuretics beta-blockers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mehler PS, Jeffers BW, Estacio R, Schrier RW. Association of hypertension and complications in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997;10:152-161.Google Scholar
  2. 2.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.Google Scholar
  3. 3.
    Curb JD, Pressel SL, Cutler JA, et al. for the Systolic Hypertension in the Elderly Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-1892.Google Scholar
  4. 4.
    Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1999; 15(Suppl. 5):46S-51S.Google Scholar
  5. 5.
    Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340:677-684.Google Scholar
  6. 6.
    Staessen JA, Fagard R, Thijs L, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.Google Scholar
  7. 7.
    Staessen JA, Thijs L, Fagard RH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998;32:404-409.Google Scholar
  8. 8.
    Wang JG, Staessen JA, Gong L, Liu L for the Systolic Hypertension in China (Syst-China) Trial Investigators. Subgroup analysis of the placebo-controlled Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000 (in press).Google Scholar
  9. 9.
    Sowers JR. Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. Am J Cardiol 1997; 79:24-28.Google Scholar
  10. 10.
    Ricciardelli B, Argenziano L, Morisco C, Monti F, Barbato E, Trimarco B. Effects of nitrendipine on plasma levels of insulin and glucose in patients with essential hypertension. Curr Ther Res 1997;58:180-186.Google Scholar
  11. 11.
    Amery A, Birkenhäger W, Bulpitt C, et al. Diuretics-a risk in the long-term treatment of hypertensive patients? J Hypertens 1988;6:925-930.Google Scholar
  12. 12.
    Epstein M. Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med 1992; 152:1573-1584.Google Scholar
  13. 13.
    Giugliano D, De Rosa N, Marfella R, et al. Comparison of nitrendipine and cilazapril in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1993;3:927-932.Google Scholar
  14. 14.
    Goa KL, Sorkin EM. Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of hypertension. Drugs 1987;33: 123-155.Google Scholar
  15. 15.
    Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997;30: 1606-1612.Google Scholar
  16. 16.
    Berkels R, Klaus W, Boller M, Roesen R. The calcium modulator nifedipine stimulates endothelial NO release in therapeutical concentrations. Pharm Pharmacol Lett 1996;6: 75-78.Google Scholar
  17. 17.
    The HOT Study Group. The Hypertension Optimal Treatment Study (The HOT Study). Blood Press 1993;2:62-68.Google Scholar
  18. 18.
    Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.Google Scholar
  19. 19.
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.Google Scholar
  20. 20.
    Tatti P, Pahor M, Byington RB, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.Google Scholar
  21. 21.
    Epstein M. Calcium antagonists and renal disease. Kidney Int 1998;54:1771-1784.Google Scholar
  22. 22.
    Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 1996;7:219-223.Google Scholar
  23. 23.
    Parving HH, Rossing P. Diabetes and risk of adverse effects with calcium antagonists. Diabetes Care 1999;21:1179-1780.Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Jerzy Gasowski
    • 1
  • Willem H. Birkenhäger
    • 2
  • Jan A. Staessen
    • 3
  • Peter W. de Leeuw
    • 4
  1. 1.Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular ResearchUniversity of LeuvenLeuvenBelgium
  2. 2.Erasmus University RotterdamThe Netherlands
  3. 3.Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular ResearchUniversity of LeuvenLeuvenBelgium
  4. 4.Department of Internal MedicineUniversity Hospital MaastrichtMaastrichtThe Netherlands

Personalised recommendations